Market News Video
MNV MNV 10 Stocks Crossing Above Their 200 Day Moving Average
Free Dividend Report - Top Ranked Stocks

Featured MNV Articles:

Notable Two Hundred Day Moving Average Cross - ICPT
Monday, July 3, 11:48 AM ET, by Market News Video Staff

In trading on Monday, shares of Intercept Pharmaceuticals Inc (ICPT) crossed below their 200 day ...

The Math Shows BBH Can Go To $140
Wednesday, July 12, 9:09 AM ET, by Market News Video Staff

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, ...

Neurocrine Biosciences Breaks Above 200-Day Moving Average - Bullish for NBIX
Wednesday, July 12, 11:39 AM ET, by Market News Video Staff

In trading on Wednesday, shares of Neurocrine Biosciences, Inc. (NBIX) crossed above their 200 day ...

Short Sellers Drawn To These Five Barry Rosenstein Holdings
Thursday, July 13, 1:58 PM ET, by Market News Video Staff

An examination of the most recent short interest data revealed these five Barry Rosenstein stocks ...

Intrexon Shares Cross Above 200 DMA
Thursday, July 13, 4:12 PM ET, by Market News Video Staff

In trading on Thursday, shares of Intrexon Corp (XON) crossed above their 200 day moving ...

  More articles:  1 2 3 4 5 6 7 next »

Acadia Pharmaceuticals (ACAD) Shares Cross Above 200 DMA

By Market News Video Staff, Thursday, January 26, 11:44 AM ET
Play Video: Learn About The 200 DMA

If the video does not load after a few moments, Upgrade to the Latest Flash Player.

In trading on Thursday, shares of Acadia Pharmaceuticals Inc (NASDAQ:ACAD) crossed above their 200 day moving average of $31.32, changing hands as high as $32.10 per share. Acadia Pharmaceuticals Inc shares are currently trading up about 0.8% on the day. The chart below shows the one year performance of ACAD shares, versus its 200 day moving average:

Acadia Pharmaceuticals Inc 200 Day Moving Average Chart

Looking at the chart above, ACAD's low point in its 52 week range is $16.64 per share, with $42.49 as the 52 week high point that compares with a last trade of $31.28.

Can your brain be trained to become a chart-predicting wizard? Click here to find out

According to the ETF Finder at ETF Channel, ACAD makes up 3.40% of the First Trust NYSE Arca Biotechnology Index Fund ETF (AMEX:FBT) which is trading lower by about 0.7% on the day Thursday.

See what other ETFs contain ACAD
See what other stocks are held by FBT

Top Six Most Viewed Stories This Week @ Market News Video:

This Article's Word Cloud:   ACAD   AMEX   Above   Acadia   According   Arca   Crossing   Finder   Fund   Looking   NYSE   Pharmaceuticals   Start   Stocks   Their   Thursday   Trust   about   above   average   below   brain   changing   chart   compares   currently   find   held   here   high   last   lower   makes   moving   other   point   predicting   range   raquo   share   shares   slideshow   that   trading   versus   week   what   which   with   your
About Us - Advertise - Contact Us - Embedding Videos - Licensing Videos - Partners - mRSS / RSS Feed - Terms of Use - Privacy Policy - Video Widget
Home  |  Analyst News  Dividend Report  ETFs  Insider Report  Large Caps  Market Movers  Week Ahead Report  Weekly Market Wrap
MNV MNV Chart Zero Stock Market Game Stock Market Definitions

Acadia Pharmaceuticals (ACAD) Shares Cross Above 200 DMA | Market News Video | Copyright © 2008 - 2017, All Rights Reserved

Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners. In no way should any content contained herein be interpreted to represent trading or investment advice. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.